Literature DB >> 22877698

In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism.

Suzan Owaisat1, Robert B Raffa, Scott M Rawls.   

Abstract

Harmine is a β-carboline compound that targets glutamatergic, monoaminergic, and GABAergic pathways underlying drug addiction. We compared the efficacy of harmine against different psychoactive drugs using an invertebrate (planarian) assay designed to quantify 'C-shape' responses. Harmine itself (0.01-10 μM) did not produce C-shapes. However, when applied over the same concentration range, harmine significantly inhibited C-shapes elicited by cocaine, with a concentration of 0.1 μM producing almost 90% inhibition. Consistent with its putative actions, harmine produced a similar, though less efficacious, inhibition of C-shapes elicited by the substituted amphetamines methamphetamine and mephedrone (4-methylmethcathinone) but was much less effective against nicotine. When tested in the presence of the glutamate transporter inhibitor dihydrokainate (DHK) (0.1, 1 μM), harmine (0.1 μM) efficacy against cocaine-induced C-shapes was significantly reduced. Harmine also attenuated C-shapes elicited by N-methyl-d-aspartate (NMDA) and by glutamate itself. The present data suggest that harmine displays preferential efficacy against different addictive substances (cocaine>amphetamines>nicotine) and, at least for cocaine, is dependent on the glutamate system.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22877698      PMCID: PMC3429366          DOI: 10.1016/j.neulet.2012.07.052

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  40 in total

1.  The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.

Authors:  Michael H Baumann; Mario A Ayestas; John S Partilla; Jacqueline R Sink; Alexander T Shulgin; Paul F Daley; Simon D Brandt; Richard B Rothman; Arnold E Ruoho; Nicholas V Cozzi
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

2.  Mephedrone ("bath salt") pharmacology: insights from invertebrates.

Authors:  L Ramoz; S Lodi; P Bhatt; A B Reitz; C Tallarida; R J Tallarida; R B Raffa; S M Rawls
Journal:  Neuroscience       Date:  2012-01-20       Impact factor: 3.590

3.  4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.

Authors:  Gregory C Hadlock; Katy M Webb; Lisa M McFadden; Pei Wen Chu; Jonathan D Ellis; Scott C Allen; David M Andrenyak; Paula L Vieira-Brock; Christopher L German; Kevin M Conrad; Amanda J Hoonakker; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-08-02       Impact factor: 4.030

4.  Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats.

Authors:  J Kehr; F Ichinose; S Yoshitake; M Goiny; T Sievertsson; F Nyberg; T Yoshitake
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

5.  Effects of harmane and other β-carbolines on apomorphine-induced licking behavior in rat.

Authors:  Davood Farzin; Abbas Haghparast; Shirine Motaman; Faegheh Baryar; Nazanin Mansouri
Journal:  Pharmacol Biochem Behav       Date:  2011-01-13       Impact factor: 3.533

6.  Interaction of mephedrone with dopamine and serotonin targets in rats.

Authors:  José Martínez-Clemente; Elena Escubedo; David Pubill; Jorge Camarasa
Journal:  Eur Neuropsychopharmacol       Date:  2011-08-06       Impact factor: 4.600

7.  Glutamate and aspartate measurements in individual planaria by rapid capillary electrophoresis.

Authors:  Chandni A Vyas; Scott M Rawls; Robert B Raffa; Jonathan G Shackman
Journal:  J Pharmacol Toxicol Methods       Date:  2010-08-12       Impact factor: 1.950

8.  Carbamazepine inhibits distinct chemoconvulsant-induced seizure-like activity in Dugesia tigrina.

Authors:  Latha Ramakrishnan; Cassie Desaer
Journal:  Pharmacol Biochem Behav       Date:  2011-06-15       Impact factor: 3.533

9.  Beta-lactam antibiotic decreases acquisition of and motivation to respond for cocaine, but not sweet food, in C57Bl/6 mice.

Authors:  Sara Jane Ward; Bruce A Rasmussen; Gladys Corley; Craig Henry; Jae K Kim; Ellen A Walker; Scott M Rawls
Journal:  Behav Pharmacol       Date:  2011-08       Impact factor: 2.293

10.  Glutamate transporter subtype 1 (GLT-1) activator ceftriaxone attenuates amphetamine-induced hyperactivity and behavioral sensitization in rats.

Authors:  Bruce Rasmussen; Ellen M Unterwald; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2011-04-27       Impact factor: 4.492

View more
  6 in total

Review 1.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

2.  Levamisole and cocaine synergism: a prevalent adulterant enhances cocaine's action in vivo.

Authors:  Christopher S Tallarida; Erin Egan; Gissel D Alejo; Robert Raffa; Ronald J Tallarida; Scott M Rawls
Journal:  Neuropharmacology       Date:  2014-01-15       Impact factor: 5.250

3.  Nicotine-induced C-shape movements in planarians are reduced by antinociceptive drugs: Implications for pain in planarian paroxysm etiology?

Authors:  Anthony Kim; Scott M Rawls
Journal:  Brain Res       Date:  2021-12-31       Impact factor: 3.252

4.  Stereochemistry and neuropharmacology of a 'bath salt' cathinone: S-enantiomer of mephedrone reduces cocaine-induced reward and withdrawal in invertebrates.

Authors:  Alexandre Vouga; Ryan A Gregg; Maryah Haidery; Anita Ramnath; Hassan K Al-Hassani; Christopher S Tallarida; David Grizzanti; Robert B Raffa; Garry R Smith; Allen B Reitz; Scott M Rawls
Journal:  Neuropharmacology       Date:  2014-12-09       Impact factor: 5.250

Review 5.  Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies.

Authors:  Lucas Silva Rodrigues; Giordano Novak Rossi; Juliana Mendes Rocha; Flávia L Osório; José Carlos Bouso; Jaime E Cecílio Hallak; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-04-29       Impact factor: 5.270

6.  Designing Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction.

Authors:  Pss Rao; Murali M Yallapu; Youssef Sari; Paul B Fisher; Santosh Kumar
Journal:  J Pers Nanomed       Date:  2015-07-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.